TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03918473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with Movement
Description: The MWM group will receive manual therapy with the following protocol: the participant will be relaxed and standing in a staggered stance with the involved foot on an eight-inch step and both feet facing forward. The clinician will be positioned in front of the participant's leg and a non-elastic belt will be placed around the distal leg of the participant and the clinician's pelvis. The clinician will then apply a sustained posteroanterior glide to the tibia through the belt by leaning backwards, while stabilizing the fixed talus and forefoot with both hands. The participant will perform a slow lunge until the end range of motion without their heel lifting off the ground. The belt will be kept perpendicular to the tibia throughout the movement and 2 sets of 10 repetitions will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrust Mobilization
Description: The talocrural joint TM will be a high velocity low amplitude manual therapy technique. This technique will be applied with the participant in the supine position on a plinth. The clinician grasps the foot with one hand with the fifth finger contacting the anterior surface of the ankle at the talus. The other hand reinforces the contact points and both thumbs are placed on the sole of the participant's foot. The clinician gives slight caudal traction focused on the talocrural joint with the ankle dorsiflexed and everted. The therapist then applies a high-velocity thrust distraction technique to the talocrural joint. Only one thrust will be applied and no audible cavitation is required. This manual therapy technique will be performed once.
Study: NCT02758314

Intervention type: OTHER
Intervention: Evaluation of PD-1/PDL-1 expression.
Description: Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects

Intervention type: OTHER
Intervention: Evaluation of PD-1/PDL-1 expression.
Description: Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
Study: NCT05133232

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynPhNe physio-neuro platform
Description: The SynPhNe device training protocol lasting approximately 60 mins:~1. Preparation for setup (\~5 mins)~2. Instruction video led warm up with active single and multi-joint movements - (\~20 mins): • Wrist extension and flexion• Fingers extension and flexion• Arm pronation and supination• Open grasp and close grasp • Open pinch and close pinch• Pronate and close grasp/ supinate and open grasp~3. Rest break - (\~5 mins)~4. Video led task practice as per the tasks below (any 4 tasks only) - (\~30 mins) • Grasp, lift and transfer water bottle using cylindrical grasp• Grasp lift and transfer pen using pinch grip• Flip pages of a book using lateral pinch grip• Use chopsticks to lift, transfer and place a small object• grasp doorknob and turn clockwise/anticlockwise, spoon scoop to pick up macaroni, open/ close a cylindrical jar, put object in pouch while holding it open and close it, fold/crease/tear a A4 size paper or fold handkerchief, reach a basket at different heights with an object.
Study: NCT01739309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study: NCT00762216

Intervention type: DEVICE
Group type: OTHER
Intervention: AcrySof® Toric intraocular lens
Description: Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
Study: NCT02806245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biventricular pacing
Description: Randomization into one of 3 study arms for acute phase and for extended phase.~Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):~1. Atrial sensing- right ventricular pacing 10 min.~2. 5 min no pacing (washout).~3. Atrial sensing - biventricular pacing 10 min.~4. 5 min no pacing (washout).~5. Intrinsic rhythm~6. 5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.~Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.~Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped.
Study: NCT01784757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 Tablet A
Description: Tablet A formulation of ODM-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 Tablet B
Description: Tablet B formulation of ODM-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-201 capsule formulation
Description: Capsule formulation of ODM-201
Study: NCT00731380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
Study: NCT03641950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).
Study: NCT01461213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1
Description: Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1
Description: Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
Study: NCT03614234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegunigalsidase alfa
Description: Recombinant human alpha galactosidase A
Study: NCT03593759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone or Prednisolone
Description: Oral prednisone/prednisolone tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone or Prednisolone
Description: Oral prednisone/prednisolone tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral, subcutaneous, or intramuscular methotrexate
Study: NCT02062827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M032 (NSC 733972)
Description: A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
Study: NCT03353584

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Therapy
Description: The VR intervention consists of an interactive audio and visual underwater experience designed to serve as a calming distraction activity. The VR software (Kind VR® Aqua) was developed by KindVR specifically for the purpose of pain distraction in a hospital setting.
Study: NCT04163484

Intervention type: OTHER
Intervention: Iodinated contrast
Description: Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
Study: NCT00912158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Non-invasive mechanical ventilation (CPAP)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BIPAP
Description: Non-invasive mechanical ventilation (BIPAP)
Study: NCT04163484

Intervention type: OTHER
Intervention: Iodinated contrast
Description: Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention

Intervention type: OTHER
Intervention: Iodinated contrast
Description: Intra-arterial injection of iodinated contrast media during percutaneous coronary intervention
Study: NCT03924856

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2, IV infusion on Days 1 and 8 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 70 mg/m\^2, IV infusion on Day 1 of each 21-day cycle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Description: Surgical RC+PLND will be done in accordance with the American Urological Association (AUA)/American Society of Clinical Oncology (ASCO)/American Society for Radiation Oncology (ASTRO)/Society of Urologic Oncology (SUO) guidelines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab by IV infusion, given on Day 1 of each 21-day cycle
Study: NCT02252874

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Slow-paced action video game
Description: 20 hours slow-paced action video games

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fast-paced action video game
Description: 20 hours fast-paced action video games

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 20 hours leisure activities
Study: NCT02423824

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
Study: NCT00678509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTK peptide mixed with Montanide ISA 51
Description: Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
Study: NCT05664048

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dry heat application
Description: Self- dry heat application on the foot during menstrual period with pain.
Study: NCT00841503

Intervention type: OTHER
Intervention: buckwheat, rice crackers, glucose, sugar substitute
Description: crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda

Intervention type: OTHER
Intervention: buckwheat, rice crackers, glucose, sugar substitute
Description: crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
Study: NCT02739594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronate
Description: Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
Study: NCT01333982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amoxycillin, Gentamicin
Description: If referral fails, community management of neonatal sepsis according to clinical algorithm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling
Description: counselling of management of neonatal sepsis in the community according to clinical algorithm.
Study: NCT03569293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Upadacitinib
Description: Tablets taken orally once a day
Study: NCT00706173

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 10-20 mg PO daily for 4 weeks.
Study: NCT03707392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ostomy Education Video
Description: Ostomy education video in addition to standard ostomy education including preoperative and postoperative ostomy nurse teaching and educational materials
Study: NCT03569293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Tablets taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets taken orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablets taken orally once a day
Study: NCT03698604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Total Laparoscopic Hysterectomy Total Abdominal hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysterectomy
Description: Total Laparoscopic Hysterectomy Total Abdominal hysterectomy
Study: NCT04065022

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS at tremor frequency
Description: tACS applied between the stimulation electrodes at tremor frequency

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS at tremor frequency
Description: tACS applied between the stimulation electrodes at tremor frequency
Study: NCT00664092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Residential
Description: living in a democratic, resident-run setting

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Residential
Description: Professionally-run substance abuse recovery setting
Study: NCT01734941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSO
Description: There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TSO
Description: There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01608789

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtue® Male Sling
Description: The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
Study: NCT01073527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hypertonic saline-salbutamol combination
Description: hypertonic saline 5% with 0.5cc salbutamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline-salbutamol combination
Description: normal saline - 4cc with salbutamol 0.5cc
Study: NCT02817555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of epoetin \> 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.~All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.~It is not anticipated that a subject will require a dose of darbepoetin \>150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.~Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate.
Study: NCT00443378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE+
Description: CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: CARE+
Description: CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
Study: NCT05158452

Intervention type: PROCEDURE
Intervention: Discussion
Description: Attend a focus group
Study: NCT03394079

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCI
Description: Percutaneous Coronary Intervention

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PCI
Description: Percutaneous Coronary Intervention
Study: NCT03803904

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spin
Description: The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spin
Description: The intervention will take place three times a week for 12 weeks and will be led by a qualified instructor (an Exercise Physiologist with five years of experience conducting the intervention). The duration of each session will be increased by 1-2 minutes to a maximum time of 45 minutes per session based on the progression of the participants and the recommendation of the instructor. Because participants are initially sedentary and detrained, exercise intensity will begin at low levels (50% of maximal heart rate reserve, HRR) but will be increased by 5% every week (if deemed necessary by the instructor) to a maximum of 75% maximal HRR.
Study: NCT02543398

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ridge preservation
Description: Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ridge preservation
Description: Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
Study: NCT00928473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A family-centered, multidisciplinary obesity treatment program
Description: The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
Study: NCT01137331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K301
Description: Liquid- applied once daily prior to bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid- applied once daily prior to bed
Study: NCT03154723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.